A system, apparatus, and method include a pump to deliver vapor including airborne contaminants including organic compounds including a target analyte; a collector to transfer the airborne contaminants by autonomous liquid extraction into a mobile organic liquid phase; a micro-fluidic chamber including immobilized biorecognition elements that bind to analytes delivered from the mobile organic liquid phase; a mechanism to introduce the mobile organic liquid phase to a buffer containing a plurality of substrates causing a series of biochemical reactions that create a change corresponding to a concentration of the target analyte; and a detector to perform real-time analysis that correlates to a concentration of the organic compounds to determine a presence of the target analyte.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

A system, apparatus, and method include a pump to deliver vapor including airborne contaminants including organic compounds including a target analyte; a collector to transfer the airborne contaminants by autonomous liquid extraction into a mobile organic liquid phase; a micro-fluidic chamber including immobilized biorecognition elements that bind to analytes delivered from the mobile organic liquid phase; a mechanism to introduce the mobile organic liquid phase to a buffer containing a plurality of substrates causing a series of biochemical reactions that create a change corresponding to a concentration of the target analyte; and a detector to perform real-time analysis that correlates to a concentration of the organic compounds to determine a presence of the target analyte.

Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: ##STR00001##
or a salt therof. R.sub.1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R.sub.2 is —N.sup.+H.sub.3, —N.sup.+H.sub.2Z, —N.sup.+HZ.sub.2, or —N.sup.+Z.sub.3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: ##STR00001##
or a salt therof. R.sub.1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R.sub.2 is —N.sup.+H.sub.3, —N.sup.+H.sub.2Z, —N.sup.+HZ.sub.2, or —N.sup.+Z.sub.3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

In one embodiment, a method includes contacting a phosphotriester and a halogen salt in a polar solvent. In another embodiment, a method for dealkylating tributylphosphate includes contacting tributylphosphate and a halogen salt in a polar solvent.

In one embodiment, a method includes contacting a phosphotriester and a halogen salt in a polar solvent. In another embodiment, a method for dealkylating tributylphosphate includes contacting tributylphosphate and a halogen salt in a polar solvent.

The invention relates to a process for dehumidifying a moist gas mixture in which the moist gas mixtures are brought into contact with an absorbent comprising dialkylimidazolium salts and trialkyl phosphate. In addition, the invention also relates to an absorption heat pump comprising the absorbent according to the invention and to the absorbent according to the invention itself.

The invention relates to a process for dehumidifying a moist gas mixture. The invention further relates to an apparatus for dehumidifying a moist gas mixture and to the use of said apparatus in the process according to the invention

Solvents useful with thiophosphoric triamide urease inhibitors, that provide stable solution of a thiophosphoric triamide, such as for distribution (in low or high concentrations) onto a fertilizer or other liquid or solid material that contains urea.